Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
Investing.com - Guggenheim has reiterated its Buy rating and $114.00 price target on Illumina (NASDAQ:ILMN), representing a 23% upside from the current price of $92.56, following Roche’s (OTC:RHHBY) pricing announcement for its AXELIOS instrument. According to InvestingPro data, Illumina trades at a P/E ratio of 12.8 and maintains a healthy gross profit margin of 68%.
Roche announced at the American Society of Human Genetics (ASHG) conference that its AXELIOS instrument will be priced at $750,000, though the company did not disclose pricing for consumables.
Guggenheim views this pricing as comparable to Illumina’s high-throughput instruments, which cost approximately $1 million with consumables priced at around $2 per gigabase.
The research firm anticipates Roche may capture some market share from Illumina, but notes this will depend on whether Roche’s consumables pricing is comparable to Illumina’s offerings.
Roche is expected to make additional announcements regarding AXELIOS throughout the ASHG conference and the remainder of 2025, though no new information about launch timing has been provided.
In other recent news, Illumina, Inc. has introduced its 5-base solution, a technology that allows researchers to detect genomic variants and DNA methylation from a single sample. This release includes two kit options for whole-genome coverage and targeted genomic regions. Additionally, Illumina’s constellation technology is being piloted by GeneDx in a study to identify complex genetic variants associated with rare diseases, showing promising results. Illumina has also launched a new business unit, BioInsight, to advance life science data analytics, focusing on developing data assets and AI solutions. This unit will be led by Rami Mehio, who has been part of Illumina’s executive leadership.
Furthermore, Illumina is collaborating with multiple global pharmaceutical companies to develop cancer diagnostics, specifically companion diagnostics for KRAS biomarkers. These partnerships aim to expand tumor-agnostic claims for KRAS alterations, which are significant in cancer development. In other industry news, BioStem Technologies has appointed Brandon Poe as its new Chief Financial Officer. Poe, who has a background in healthcare and life sciences finance, previously held a leadership role at Illumina.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.